Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known about the safety of HLA-mismatched DLI for the treatment of relapse. We examined the outcome of 58 consecutive leukaemia patients who received escalating-dose DLI for treatment of relapse after alemtuzumab-conditioned myeloablative unrelated donor HSCT at our institution. High-resolution HLA typing on stored DNA samples revealed mismatches in 28/58 patients who were considered HLA-matched at the time of transplantation. Following DLI from HLA-matched (10/10) (n ¼ 30) or -mismatched (7-9/10) (n ¼ 28) unrelated donors, we found no significant difference in the incidence of acute GVHD (17.2% versus 23.1%, P ¼ 0.59), probability of remission at 3 years (62.1% versus 63.9%, P ¼ 0.89) or 5-year OS (89.8% versus 77.7%, P ¼ 0.22). We conclude that escalating-dose DLI can be safely given to HLA-mismatched recipients following T-depleted myeloablative HSCT.
INTRODUCTION
Allogeneic haematopoietic SCT (HSCT) remains the only curative treatment strategy for a number of haematological malignancies. [1] [2] [3] However, for many patients identification of a suitable donor remains challenging. While a 10/10 HLA-matched sibling remains the favoured option, 70% of patients do not have a sibling donor, 4 and a matched unrelated donor (MUD) is often the preferred alternative. Despite the availability of international donor registries, identification of a fully matched donor still remains problematic, and in 40% no such donor can be identified. 5 The use of increasingly sensitive methods of HLA typing permits the identification of disparities that would have historically remained unmasked. Modified conditioning regimens, often with T-cell depletion, have facilitated the use of mismatched donors for these patients, 6 ,7 albeit with increased TRM and complications. 8 However, the combination of T-cell depletion and increasingly sensitive methods of minimal residual disease detection results in early relapse detection. 9, 10 DLI is a safe and powerful strategy to treat post-HSCT relapse in sibling and MUDtransplant recipients. [11] [12] [13] [14] Indeed registry data suggest that between 16 and 40% of patients undergoing HSCT will receive post-transplant DLI for the treatment of relapse or mixed chimerism. While the use of T-cell depletion may permit HLA mismatch during the initial transplant phase 5, 6 and reduce the probability of developing acute GVHD (aGVHD), 15, 16 the degree to which HLA mismatch influences the probability of response, risk of GVHD post DLI and OS is unclear. 17 With the advent of increasingly permissive transplant regimens and increasing numbers of mismatched unrelated donors (MMUDs), the question of whether it is safe to give DLI to a mismatched recipient is very pertinent. The aim of this retrospective landmark analysis was to determine the effects of HLA disparity on the probability of developing aGVHD following DLI.
PATIENTS AND METHODS

Patient eligibility and study design
In this study, we retrospectively performed high-resolution HLA typing on stored genomic DNA samples and analysed the outcome of 58 consecutive patients who underwent escalating-dose DLI for the treatment of relapse or mixed chimerism following an alemtuzumab-based myeloablative unrelated donor transplant at our institution between December 1995 and August 2010. High-resolution HLA typing for HLA-A, B, C, DR and DQ was performed on stored genomic DNA by direct sequencing and the cohort stratified according to the presence or absence of an HLA mismatch. Details of recipient-donor matching are shown in Table 1 . The research protocol was approved by the Local Research Ethics Committee and all patients gave written informed consent in accordance with the Declaration of Helsinki.
Transplant protocol
All patients received uniform conditioning with 14.4 Gy of fractionated TBI on days À 4 to À 2, i.v. CY (120 mg/kg total dose) on days À 5 and À 6, or etoposide (60 mg/kg) on day À 5 and in vivo T-cell depletion with alemtuzumab 10 mg i.v. daily on days À 10 to À 6. GVHD prophylaxis consisted of CYA from day À 3 onwards and MTX (8 mg/m 2 ) on days þ 2, þ 4, þ 8 and þ 12. BM (n ¼ 45) or PBSCs (n ¼ 13) were infused on day 0.
DLI protocol
At relapse, all patients received DLI using a previously established escalating-dose regimen. 10 A starting dose of 1 Â 10 6 T cells/kg was given followed by increasing doses at 3-6 monthly intervals (1 Â 10 6 , 1 Â 10 7 , 5 Â 10 7 and 1 Â 10 8 T cells/kg) in the absence of GVHD. 12 All patients had stopped immunosuppression prior to administration of DLI.
HLA typing
High-resolution HLA typing was performed by DNA sequencing on stored DNA using Invitrogen SeCore(R) kits (Paisley, UK). Class 1 Ags (HLA-A, B and C) were determined using locus-specific primers that sequence exons 2, 3 and 4, whereas class 2 Ags (HLA-DRB1 and DQB1) were determined using group-specific primers sequencing exon 2 as the only site of significant polymorphisms. The nucleotides and resulting HLA types were determined using multicolour sequence analysis, and based on the sequence data, the HLA type was assigned using computer software (SBTengine from GenDx, Utrecht, Netherlands).
Outcome assessment and statistical analysis
The primary end point was aGVHD within 100 days of DLI. Secondary end points included incidence and severity of chronic GVHD (cGVHD), probability of achieving remission post DLI and OS. GVHD was graded using the modified Glucksberg criteria. 18, 19 Comparisons of aGVHD and cGVHD outcomes between the HLA-matching categories were made using w 2 or Fisher's Exact tests. Probabilities of remission were calculated using the cumulative incidence procedure, and the Kaplan-Meier method was used for OS; categories were compared by log-rank or Grey's test. P-values reflect two-sided test results.
RESULTS
Patient characteristics
Fifty-eight patients had stored DNA available for retrospective high-resolution HLA typing. Thirty patients were fully matched at all 10 loci, whereas high-resolution HLA typing uncovered mismatches not detected prior to transplantation by low-or medium-resolution HLA typing in 28 patients (HLA-A n ¼ 3, HLA-B n ¼ 4, HLA-C n ¼ 15, HLA-DR n ¼ 8 and HLA-DQ n ¼ 12). Mismatches were present at 1, 2 or 3 loci in 18, 6 and 4 patients, respectively. Clinical characteristics of the patients, stratified according to the presence or absence of an HLA mismatch, are shown in Table 1 . The groups were comparable with regard to baseline and transplant demographics, with the exception that there were more male recipients from female donors in the mismatched group compared with the matched group (n ¼ 7 versus n ¼ 2, P ¼ 0.05). There were no significant differences between MUD and MMUD groups in terms of age, sex, indication for transplantation, stem cell source or dose and incidence of acute and chronic GVHD post HSCT (prior to infusion of DLI).
The median time from HSCT to first DLI was 15 months (range 6-76) in MUD recipients and 16 months (range 5-79) in MMUD recipients (P ¼ 0.83).The median number of DLI was 2 (range 1-6) in both groups, with a median dose of 11 Â 10 6 /kg (range 1-361 Â 10 6 /kg) in both groups.
Response to DLI Indications for DLI included disease relapse (n ¼ 57) or mixed chimerism (n ¼ 1); 41 patients (71%) re-entered CR, defined as complete molecular remission in the case of CML (undetectable BCR-ABL1 transcripts by PCR on two consecutive occasions) or complete morphological remission for other forms of leukaemia (o5% blasts on BM morphology). Remission was achieved post DLI in 22/30 MUDs and 19/28 MMUDs (probabilities of 62.1 and 63.9% at 3 years, respectively, P ¼ 0.89) Toxicity, GVHD and outcome Three patients died within 100 days of DLI without evident aGVHD and were excluded from aGVHD analysis (causes of death included progressive disease, fungal infection and severe haemolytic anaemia). The incidence of aGVHD following DLI was low and not significantly different between MUD and MMUD recipients for all grades; 5 of 29 (17.2%) MUD and 6 of 26 (23.1%) MMUD recipients developed grade 2-4 aGVHD following infusion of DLI (P ¼ 0.59), with a median time to aGVHD onset of 38 (range 17-58) and 34 (range 20-82) days from the preceding DLI, respectively (P ¼ 0.88) ( Table 2) . Importantly, the rates of aGVHD post DLI were significantly lower than the rates of aGVHD in the immediate posttransplant period, which were 47% and 50%, respectively (also not significantly different in the two groups, P ¼ 0.80) ( Table 2) . Furthermore, aGVHD in the immediate post-transplant period did not predict the development of aGVHD following infusion of DLI. Of the 28 patients with a history of grade 2-4 aGVHD post transplant, 6 (21%) developed aGVHD post DLI compared with 5 (19%) of the 27 patients who had no post-transplant aGVHD, with no impact of HLA disparity (P ¼ 0.87).
Similarly, we found no significant difference in the rates of overall cGVHD between the groups; 10 of 29 (34%) MUD and 11 of 26 (42%) MMUD recipients developed cGVHD (P ¼ 0.51) following DLI. However, we observed a trend towards more severe cGVHD The OS at 5 years was 86% for the whole cohort, with no significant difference between MUD and MMUD recipients, 89.8% and 77.7%, respectively, P ¼ 0.22 ( Figure 1) . The most frequent cause of death in both groups was infection (n ¼ 2 in the matched and n ¼ 3 in the mismatched groups). GVHD accounted for one death in the mismatched group and contributed, along with infection, to the death of one of the matched recipients.
An exploratory analysis of the outcomes of DLI from MMUDs at one locus (n ¼ 18) versus 2 or more loci (n ¼ 10) was also performed. We found no significant difference in the rates of grade 2-4 aGVHD or cGVHD in recipients of DLI mismatched at 1 versus X2 loci (31% versus 11%, P ¼ 0.22 and 38% versus 50%, P ¼ 0.53, respectively).
Impact of time to DLI on outcome Patients receiving DLI within 9 months of HSCT (n ¼ 9) had a significantly inferior survival to those receiving DLI more than 9 months after HSCT (n ¼ 51) (5 years OS 33.3 and 93.3%, respectively, Po0.01) (Figure 2 ). We found no significant difference in the rates of HLA mismatch in patients who received DLI within 9 months of HSCT (44.4% versus 44.9%, respectively, P ¼ 0.98). Six of the nine patients who received DLI o9 months after HSCT died, all within 12 months of receiving DLI. Importantly, although only 15% of patients received DLI o9 months post HSCT, they accounted for 46% of all deaths. Causes of death were progressive disease in three, severe bacterial infection in one, fungal infection in one and severe haemolytic anaemia in one patient (Table 3 ). There was no significant difference in the rates of aGVHD in the two groups (33% versus 19%, P ¼ 0.58), although this result was confounded by early deaths post DLI. All three surviving patients achieved CR post DLI.
DISCUSSION
Allogeneic HSCT challenges one of the fundamental hallmarks of cancer, the tumour's ability to evade immune surveillance. 20 The success of HSCT depends on achieving the optimal balance between sufficient immunosuppression to allow engraftment and the development of immune tolerance to the graft while establishing adequate GVL effect to generate a sustained attack on the malignant clone. DLI remains a key tool in modulating the balance between the linked GVHD/GVL effect and relapse, 9,10 but the associated risk of GVHD and the complications related to its management remain a major challenge for both patients and clinicians. Careful work has previously established safe and effective protocols to maximise the ability of DLI to restore disease control, whilst minimising the risk of GVHD. 14, 21 However, these protocols were established in the context of HLA-matched sibling 22 and fully MUD transplants. 9, 10 Whilst there is an increasing literature on transplant regimens permitting the use of MMUD as a source of stem cells, the safety of DLI in this setting remains largely unclear. Existing studies comprise mainly small data sets on modified DLI regimens, and more work is therefore needed to establish the safety of such an approach. 16, 23 Here, we examined the outcomes of 58 consecutive MUDtransplant recipients who were treated on a uniform escalatingdose DLI protocol at our centre. Retrospective high-resolution typing revealed mismatches not detected prior to transplantation Abbreviations: aGVHD, acute GVHD; cGVHD, chronic GVHD; HSCT, hematopoietic SCT. by low-or medium-resolution HLA typing in 28 patients. We report that DLI, using an escalating-dose regimen, can be safely given to mismatched transplant recipients following alemtuzumabbased myeloablative allo-SCT without a significant impact on GVHD or OS. A large proportion of the patients included in our study were transplanted for chronic-phase CML. Whilst in the era of tyrosine kinase inhibitors CML is a less frequent indication for transplantation, 1 the exquisite sensitivity of CML to the GVL effect has historically provided important insights into the mechanisms of GVL, and have helped further our understanding of immunological responses against leukaemia. 24 Moreover, this study primarily addresses the safety and efficacy of DLI many months after transplantation, away from the cytokine storm of high-dose therapy, and after immune reconstitution and development of tolerance, making the underlying disease less important in the assessment of acute or chronic GVHD. The study of CML patients also allowed us to objectively assess the effect of mismatched DLI on the GVL effect using a sensitive molecular marker. We found no significant difference in the remission rates between the two groups, indicating that DLI from a mismatched donor is likely to be just as effective at inducing a GVL response as in the HLA-matched setting. In this context, these results are important in that they support safe and effective use of DLI from mismatched donors following T-depleted myeloablative HSCT for CML, and support further exploration of DLI from mismatched donors in other GVL-sensitive diseases.
However, while we observed that DLI from both MUD and MMUD was safe and effective in patients who relapsed late after their myeloablative T-depleted allograft, its use in the early post-transplantation period was associated with significantly worse outcome. These data are in keeping with previous reports that administration of DLI in the immediate post-transplant period is complicated by a high risk of severe, sometimes fatal, GVHD. 11, 25 In summary, this study demonstrates that DLI, using an escalating-dose regimen, can be safely given to mismatched transplant recipients following alemtuzumab-based myeloablative allo-SCT, with the ability to deliver a high rate of molecular remission with a low risk of GVHD. The timing of DLI appears to be crucial, with worse outcome seen in those patients receiving DLI in the early post-HSCT period. The advent of targeted therapies such as tyrosine kinase or FLT 3 inhibitors and immunomodulatory drugs such as 5-azacytidine may have relevance for the design of DLI protocols in diseases such as CML, Ph-positive ALL or AML. In these settings, the combination of these drugs might modify relapse kinetics such that DLI, if required from a matched or MMUD, and can be delivered safely and effectively. 26, 27 
